Johnson & Johnson will report fourth-quarter results before markets open on January 21. Analysts currently expect year-over-year revenue growth of around 5%, with strength in the medical technology and pharmaceutical segments offsetting pressure from the loss of exclusivity on its leading immunology franchise. Management commented in early January that China sales trends had shown signs of stabilization, but persistent reimbursement headwinds and competitive pricing in emerging markets could temper top-line expansion. Investor focus will center on any updates to full-year 2026 guidance, particularly sales forecasts for newly launched oncology and neuroscience therapies and capital allocation plans following the recent consumer health spinoff.

In the third quarter, Johnson & Johnson generated $24 billion in revenue, up 4.4% year-over-year, and delivered adjusted operating margin of 30.2%, driving a 15.7% increase in EPS. Free cash flow reached $5.1 billion for the quarter, contributing to $14.3 billion over the first nine months of 2025, while dividend payments totaled $9.3 billion in the same period. Shares have rallied more than 50% over the past 12 months and now trade above 21 times forward earnings, significantly exceeding the company’s long-term average of 17 to 18 times. Although fundamentals remain solid, the current valuation offers a limited margin of safety, leading several strategists to lower their recommendations to neutral.

The company’s dividend yield stands at 2.37%, reflecting an annual payout of $5.20 per share. With a payout ratio of 48.9% and 63 consecutive years of dividend increases, it remains a hallmark of predictable income for shareholders. Based on a hypothetical holding of 1,000 shares, investors can anticipate roughly $5,200 in dividends annually—equivalent to approximately $433 per month. Those seeking to generate at least $500 of monthly income could achieve this by combining existing Johnson & Johnson dividends with modest positions in complementary high-yield names, leveraging the firm’s continued free cash flow generation and commitment to returning capital to shareholders.